MicroRNAs in systemic rheumatic diseases by Ceribelli, Angela et al.
Introduction
Since their initial discovery in 1993 [1], microRNAs 
(miRNAs) have been studied extensively due to their role 
in the regulation of almost every cellular process thus far 
investigated. miRNAs are non-coding RNAs about 21 
nucleotides in length that function as post-transcriptional 
regulators of gene expression [2]. Th   ey can inﬂ  uence the 
activity of about 50% or more of all protein-coding genes 
in mammals [2], and their change in expression is 
associated with human diseases, including infectious 
diseases, cancer, and rheumatic diseases [3-5]. Over 800 
human miRNAs have been identiﬁ  ed so far [2], and they 
have been shown to negatively regulate protein expres-
sion through the inhibition of translation and/or decrease 
in mRNA stability [6-8]. It is now apparent that miRNAs 
can potentially regulate every aspect of cellular activity, 
from diﬀ  erentiation and proliferation to apoptosis, and 
they can also modulate a large range of physiological and 
pathological processes [6].
Biogenesis and function of miRNAs
Th  e  ﬁ  rst step in the biogenesis of mammalian miRNAs is 
the generation of primary miRNA transcripts (pri-miRNAs) 
in the nucleus [2]. Th   e pri-miRNAs fold into hairpins and 
act as substrate for Drosha, which is one of the two 
members of the RNase III family involved in the miRNA 
maturation process. Th   e product of Drosha cleavage, an 
approximately 70-nucleotide precursor miRNA (pre-
miRNA), is exported to the cytoplasm where Dicer, the 
second RNase III family member, processes the pre-
miRNA to a 20- to 23-nucleotide miRNA/miRNA* duplex 
[2]. Th  e preferential loading of one miRNA strand (the 
guiding strand or mature miRNA) onto the RNA-induced 
silencing complex (RISC) over the other strand (passenger 
strand, miRNA*) apparently is based on the thermo-
dynamic stability of the miRNA duplex. Th  e mature 
miRNA with RISC will bind to and silence its target 
mRNA based on seed sequence complementarity, 
generally at the 3’ UTR. Th   e miRNA* may be discarded 
and eventually degraded [8,9], but recent reports are 
showing that some miRNA* are stably expressed and they 
are implicated in important functions as well [9]. An   
interesting example is the report of Zhou and colleagues 
[10] demonstrating upregulation of miR-155 and 
miR-155* in human plasmacytoid dendritic cells to co-
ordinate function in stimulating type I IFN production.
Since the ﬁ   rst miRNAs discovered (lin-4 and let-7) 
were shown to bind the 3’ UTR of target mRNAs, it has 
been widely believed that miRNAs exert their eﬀ  ects 
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sequences in the 3’ UTR only. Th  e imperfect comple-
mentarity still requires perfect target matching of the 
second through the seventh nucleotides (‘seed sequence’) 
starting from the 5’ end of the miRNA [3]. However, it 
has been recently shown that miRNAs can also bind to 
the 5’ UTR region and to protein coding sequences, albeit 
causing relatively weak repression [3]. Another very 
recent study challenged the traditional seed match 
principle by demonstrating a novel centered pairing 
between miRNA and mRNA, the ‘centered sites’, which 
consist of a class of miRNA target sites that lack both 
perfect seed pairing and 3’ compensatory pairing and 
have 11 to 12 contiguous Watson-Crick pairs of miRNA 
nucleotides 4 to 15 [11]. Th   is leads to more versatility in 
miRNA regulation of speciﬁ   c targets and, more 
importantly, may fail to be predicted by the most 
common algorithms designed to detect miRNA binding 
sites in the 3’ UTR [11]. Other recent studies have also 
shown the ability of certain miRNAs in translational 
activation [12], which suggests that our knowledge of 
overall biological function for miRNAs remains some-
what incomplete.
Key macromolecules of RISC are targets of human 
autoantibodies
Th   e two best characterized protein families in the RISC 
complex, the Argonaute family and GW182 (glycine-
tryptophan dipeptide-rich protein of 182 kDa), are 
known to play a central role in silencing mRNA trans-
lation as well as triggering mRNA degradation. Th  ey  are 
essential components of the GW bodies (also known as 
mammalian processing bodies, or P bodies). Interestingly, 
both are known autoantigens recognized by autoanti-
bodies in various disease states [13-15]. Th  e Argonaute 
family comprises four Argonaute (Ago) proteins (Ago1 to 
4) in mammals, and they have all been shown to interact 
with miRNAs [16,17] and repress protein translation 
when artiﬁ   cially tethered to the 3’ UTR of reporter 
mRNAs [18,19]. However, Ago-mediated repression 
requires them to interact with another protein, GW182, 
which is the key silencer downstream of Ago2 [19]. 
GW182 (also known as TNRC6A) is a 182-kDa protein 
characterized by multiple glycine (G) and tryptophan 
(W) motifs and is a very important constituent of GW 
bodies [20,21]. Th  e GW182 family includes three para-
logues of TNRC6 (GW182-related) proteins, GW182/
TNGW1, TNRC6B (containing three isoforms), and 
TNRC6C, in mammals [22,23]. A number of diﬀ  erent 
models have been proposed for the GW182 silencing 
mechanism in the miRNA pathway, including its 
interference with translational initiation and 80S complex 
assembly as well as post-initiation steps, but the detailed 
molecular process remains to be explored [8,9]. Recent 
studies also demonstrated that GW182 interacts with 
Poly-A binding protein (PABP) and further recruits 
deadenylase complex to promote miRNA-targeted 
mRNA decay [24,25]. GW182 was originally identiﬁ  ed 
and cloned in 2002 as a novel protein recognized by an 
autoimmune serum from a patient with motor and 
sensory neuropathy [15,26]. In 2006, Jakymiw and 
colleagues [13] showed that the Ago2 protein corresponds 
to the 100-kDa component of the so-called ‘anti-Su 
antibodies’, and for this reason we now call these 
antibodies ‘anti-Ago2/Su’. Since their identiﬁ  cation 
[27,28], anti-Ago2/Su antibodies have been detected in 
various diseases, including autoimmune and infectious 
disease [13,15,28-30]. However, the clinical signiﬁ  cance 
of anti-Ago2/Su antibodies has not been established yet 
[15,30].
MicroRNAs in rheumatic diseases
As miRNAs emerge to play important roles in many 
biological processes, they have been referred to as master 
regulators of gene expression, with a concept where a 
single miRNA may regulate an entire pathway or even 
multiple pathways [6]. Regulation of the immune system 
is vital to prevent many pathogenic disorders and 
mammals have developed a complex system of checks 
and balances for immune regulation in order to maintain 
self-tolerance while allowing immune responses to 
foreign pathogens [5]. Only in recent years has more 
evidence emerged to support a central role for miRNAs 
also in abnormal immune processes and in rheumatic 
diseases. In fact, the potential of miRNAs as biomarkers 
in rheumatic diseases is a new and growing area of 
research [3,5]. Th  e identiﬁ  cation of candidate miRNAs 
that target genes implicated in rheumatic disorders and 
the evaluation of the consequences of mutations in their 
target sites coupled to phenotypic and gene expression 
studies should improve our understanding of the mole  cu-
lar mechanisms responsible for rheumatic diseases [31]. 
Increased knowledge of miRNAs has led to the develop-
ment of mouse models for studying in vivo therapeutic 
approaches using speciﬁ   c miRNAs [32]. In particular, 
Nagata and colleagues [32] have performed the intra-
articular injection of double-stranded miR-15a in the 
synovium of mice with autoantibody-mediated arthritis. 
Th  rough this experiment, they have shown that this 
miRNA is capable of cell entry and induces cell apoptosis 
through targeting Bcl-2, which is known normally to 
suppress apoptotic processes [32].
miR-146a appears to be an interesting example of a 
master regulator in several aspects of immunity. Speciﬁ  -
cally, it contributes to controlling the overproduction of 
cytokines, such as TNF-α, and it functions as a negative 
feedback control of innate immunity in toll-like receptor 
(TLR) signaling during recurrent bacterial infection by 
Ceribelli et al. Arthritis Research & Therapy 2011, 13:N 
http://arthritis-research.com/content/13/4/229
Page 2 of 10establishing endotoxin tolerance [33] and cross-tolerance 
[34]. Lu and colleagues [35] recently demonstrated that 
miR-146a is critical for the suppressor functions of 
regulatory T (Treg) cells. In fact, a miR-146a knockout 
mouse showed some loss of immunological tolerance, 
responsible for fatal IFNγ-dependent immune-mediated 
lesions in diﬀ  erent organs [35]. Th   is is an example of how 
speciﬁ  c cellular aspects can also be controlled by a single 
miRNA, where the lack of function of miRNAs can be 
responsible for the onset of autoimmune disease. In 
another study, Curtale and colleagues [36] showed that 
miR-146a is involved in T-cell activation and is highly 
expressed in mature human memory T cells. miR-146a 
can modulate activation-induced cell death processes, 
thus acting as an anti-apoptotic factor in T cells, and it is 
also able to reduce the expression of cytokines, such as 
IL-2, induced by T-cell receptor engagement in the 
adaptive immune response [36].
Another miRNA widely studied for its key role in 
autoimmunity is miR-155. It functions in the hemato-
poietic compartment to promote the development of 
inﬂ  ammatory T cells, including the T helper (Th  )17  and 
Th  1 cell subset [37]. Divekar and colleagues have 
investigated the inﬂ  uence of miR-155 on Treg cells in a 
mouse model (MRL/lpr) of systemic lupus erythematosus 
(SLE) [38]. Th   ese investigators have shown an increase in 
CD4+CD25+Foxp3+ Treg cells that have an altered 
phenotype and reduced suppressive capacity. Searching 
for the reason for this alteration, they detected a 
signiﬁ  cant reduction of Dicer expression and the over-
expression of some miRNAs in MRL/lpr Treg cells, 
including miR-155, which is able to target CD62L in Treg 
cells. Th   e results of this study show that elevated miR-155 
expression together with a reduced level of Dicer can be 
responsible for the Treg cell phenotype in MRL/lpr mice 
[38]. Th   is study also introduces a new concept that some 
miRNAs may be produced in this SLE model indepen-
dently of Dicer, as described recently in mouse embryonic 
stem cells [39]. miR-155 also plays an important role in 
mouse models of collagen-induced arthritis and K/BxN 
serum transfer arthritis [40]. In fact, miR-155 knockout 
mice do not develop collagen-induced arthritis. In the 
K/BxN serum transfer arthritis model, the miR-155-/- 
mice show a reduction in pathogenic autoreactive B and 
T cells and cytokine production (IL-6, IL-17 and IL-22) 
and local bone destruction is reduced because of a 
decreased generation of osteoclasts [40]. Th  ese results 
support a possible therapeutic role for miRNAs in 
rheuma  toid arthritis (RA).
Beside immune and autoimmune mechanisms, the 
study of miRNAs as biomarkers is most advanced in 
oncology [3]. Initial reports showed that cancer cells and 
tissues have diﬀ  erent miRNA proﬁ  les from normal cells 
and tissues, suggesting that they could be used for 
diagnosis, prognosis and therapeutic outcome [3]. By the 
regulation of gene expression at the post-transcriptional 
level, they aﬀ  ect various signaling cascades during the 
progression of neoplastic diseases [41]. Sustained angio-
genesis is one of the mechanisms leading to cancer pro-
gres  sion. Recently, a role of the secreted protein epider-
mal growth factor-like domain 7 (EGFL7) in the control 
of vascular tubulogenesis has been suggested. Interest-
ingly, the two biologically active miRNAs miR-126 and its 
complement miR-126*, which are encoded by intron 7 of 
the EGFL7 gene, have been shown to mediate vascular 
functions [41], promoting blood vessel growth and in-
ﬂ   am  mation. Complex networks of reprogramming of 
miRNAs have been detected in cancer and leukemia and, 
given the critical role that miRNAs play in tumorigenesis 
processes and their disease-speciﬁ  c expression, they have 
the potential to become therapeutic targets and speciﬁ  c 
cancer biomarkers [42,43].
In the present review, we will focus our attention on 
recent developments in understanding the role of miRNAs 
in autoimmune rheumatic diseases, such as SLE, RA, 
systemic sclerosis (SSc; scleroderma), Sjögren’s syndrome 
(SS) and polymyositis/dermatomyositis (PM/DM).
Systemic lupus erythematosus
SLE is a systemic inﬂ   ammatory autoimmune disease 
characterized by the presence of autoantibodies against a 
large number of self-antigens, including chromatin, ribo-
nucleoproteins, and phospholipids. Clinical manifesta-
tions are heterogeneous and include malar rash, photo-
sensitivity, arthritis, glomerulonephritis, and neurological 
disorders [5,44,45]. Since 2007, diﬀ   erent groups have 
reported altered miRNA expression in tissues and 
peripheral blood mononuclear cells (PBMCs) from SLE 
patients [46,47], but these ﬁ  rst reports mainly identiﬁ  ed 
groups of miRNAs that were aberrantly expressed 
through microarray chip analysis, without deﬁ  ning 
poten  tial pathways they participate in. Table 1 summar-
izes studies that are more focused on the identiﬁ  cation of 
speciﬁ  c aberrant miRNAs in SLE and other diseases. For 
example, Tang and colleagues [48] have studied the role 
of miR-146a, showing that it is down-regulated in SLE. 
Th   ey have evaluated the IFN score through the 
expression levels of the IFN signature genes OAS1, MX1, 
and LY6E [48]. Since it is known that miR-146a targets 
adaptors TRAF6 (TNF receptor-associated factor 6) and 
IRAK1 (IL-1 receptor-associated kinase 1) in the pathway 
to NF-κB activation (Figure 1a), they have postulated that 
the lower expression levels of miR-146a in lupus PBMCs 
is inversely correlated with the IFN score and may be 
responsible for IFN overproduction in SLE [48]. Th  ey 
have also demonstrated that low miR-146a and high IFN 
expression correlate with SLE disease activity, in 
particular with renal disease [48].
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reporting that the miR-125a level is reduced in PBMCs 
from SLE patients, and the expression of the predicted 
target of miR-125a, KLF13, was increased [49]. Th  e  ﬁ  nal 
result is the signiﬁ   cant over-expression of the inﬂ  am-
matory chemokine RANTES (Regulated upon activation, 
normal T-cell expressed, and secreted; also called CCL5), 
which is known to be highly expressed and have 
detrimental eﬀ  ects in inﬂ  ammatory processes, including 
arthritis and nephritis (Figure 1b). Th  is  study 
demonstrated that miR-125a negatively regulates 
RANTES expression by targeting KLF13, as shown by 
manipulation studies of activated T cells from lupus 
patients [49].
Table 1. Aberrant miRNA expression in autoimmune rheumatic diseases
MicroRNA Source  Target  mRNA  Aff  ected pathway and fi  nal eff  ect  Reference
Systemic lupus erythematosus       
 Down-regulated  miRNAs       
  miR-146a  PBMCs  TRAF6, IRAK1  Type I IFN overproduction   [48]
  miR-125a  PBMCs  KLF13  RANTES (CCL5) overproduction  [49]
 Up-regulated  miRNAs       
  miR-21,  miR-148a  PBMCs  RASGRP1, DNMT1  DNA methylation  [50]
  miR-126  PBMCs  DNMT1  DNA methylation  [51]
     
Rheumatoid arthritis       
 Down-regulated  miRNAs       
  miR-124a  Synoviocytes  CDK2, MCP-1  Synovial cell proliferation, leukocyte   [63]
        chemotaxis,  and  angiogenesis
 Up-regulated  miRNAs       
    miR-146a  PBMCs and fi  broblasts from   TRAF6, IRAK1  NF-kB, leading to prolonged production of  [3,55]
    synovial  tissue    proinfl  ammatory cytokines/chemokines, 
        including  TNF-α  and  IL-1β
    miR-155  Synovial tissue and fi  broblast-  -  MMP-3 and MMP-1 production, causing  [56]
    like  synoviocytes    joint destruction
  miR-203  Synovial  fi   broblasts  -  NF-kB, leading to increased production   [58]
          of MMP-1 and IL-6, and to the activated 
          phenotype of synovial fi  broblasts
  miR-223  CD4+  naïve  T  cells  -  Unknown; possible role in RA pathogenesis?  [59]
  miR-346  Fibroblast-like  synoviocytes  IL-18 mRNA  LPS-induced Bruton’s tyrosine kinase   [60]
        expression;  turn-off   IL-18 expression in 
        response  to  LPS
     
Sjögren’s syndrome       
 Down-regulated  miRNAs       
    miR-17-92 cluster  Minor salivary glands  -  Accumulation of pro-B cells, marked   [67]
          reduction of pre-B and more mature B cells
 Up-regulated  miRNAs       
    miR-146a  PBMCs of SS patients; PBMCs,   TRAF6, IRAK1  NF-kB, causing increased phagocytic activity,   [69]
      salivary and lacrimal glands     suppressed infl  ammatory cytokine
      of SS mouse model    production 
     
Scleroderma      
 Down-regulated  miRNAs       
    miR-29  Skin fi  broblasts and skin   COL3A1  PDGF-B and TGF-β, leading to increased  [71]
    sections    production of type I and type III collagen  [71]
     
Polymyositis/dermatomyositis      
    miR-146b, miR-155,   Muscle specimens  -  NF-kB pathway (miR-146)  [73]
  miR-214,  miR-221,  miR-222
CDK2, cyclin-dependent kinase 2; DNMT1, DNA methyltransferase 1; IRAK1, IL-1 receptor-associated kinase 1; LPS, lipopolysaccharide; MCP-1, monocyte 
chemoattractant protein 1; MMP, matrix metalloproteinase; PBMC, peripheral blood mononuclear cell; PDGF, platelet-derived growth factor; RA, rheumatoid arthritis; 
RANTES, Regulated upon activation, normal T-cell expressed, and secreted; RASGRP1, RAS guanyl-releasing protein 1; SS, Sjögren’s syndrome; TGF, transforming 
growth factor; TRAF6, TNF receptor-associated factor 6.
Ceribelli et al. Arthritis Research & Therapy 2011, 13:N 
http://arthritis-research.com/content/13/4/229
Page 4 of 10While miR-146a and miR-125a are down-regulated in 
SLE patients, other miRNAs can be up-regulated, as is 
the case for miR-21, miR-148, and miR-126 (Figure 1c) 
[50,51]. In contrast, miR-21 and miR-148 are over-
expressed in PBMCs of SLE patients, and it has been 
demonstrated that they can target the DNA-methylation 
pathway, causing DNA hypomethylation and over-
expres  sion of autoimmune-associated methylation-
sensitive genes, such as CD70 and LFA-1 (CD11a) [50]. 
Th   e same targets are also inﬂ  uenced by another miRNA, 
miR-126, which is also directed to the EGFL7 gene. In 
this case, the ﬁ  nal result is the DNA hypomethylation 
and overexpression of autoimmune-associated genes, 
leading to the autoimmune response in SLE [51].
Rheumatoid arthritis
RA is a systemic autoimmune disorder characterized by 
chronic inﬂ  ammation of synovial tissue that results in 
irreversible joint damage [52]. Inﬂ  ammatory cytokines, 
especially TNF-α, IL-1β, and IL-6, are known to play an 
important role in the pathogenesis of RA, as the inhi  bi-
tion of these cytokines can ameliorate disease symp  toms 
in patients [53]. In recent years, many studies have 
focused on the identiﬁ  cation of altered miRNA expres-
sion in RA patients compared to healthy controls or 
patients aﬀ  ected by osteoarthritis [54-56]. Some studies 
mainly considered miRNA expression in plasma and 
serum, while others mainly focused on tissue analysis 
(Table 1) [57]. Two of these studies examined miRNA 
expression in RA synovial tissue and ﬁ  broblasts. Stanczyk 
and colleagues [56] reported an increase of miR-155 and 
miR-146a expression in both RA synovial ﬁ  broblasts 
(RASFs) and RA synovial tissue compared to osteo-
arthritis patients. Th   ese investigators concluded that the 
inﬂ  ammatory milieu of RA may alter miRNA expression 
proﬁ   les in resident cells of the rheumatoid joints. 
Figure 1. Contribution of aberrant miRNA expression in SLE PBMCs. (A) miR-146a is down-regulated in systemic lupus erythematosus (SLE) 
peripheral blood mononuclear cells (PBMCs) and this may amplify the activation of NF-kB through its direct regulation of NF-kB upstream regulators 
IRAK1 (IL-1 receptor-associated kinase 1) and TRAF6 (TNF receptor-associated factor 6). Activation of NF-kB leads to increased type I IFN production 
and thus increased expression of ‘IFN signature genes’, including LY6E, OAS1, and MX1 [48]. (B) miR-125a is down-regulated in PBMCs from SLE 
patients, which leads to elevated expression of its target transcriptional factor KLF13. KLF13 can trigger the expression of the pro-infl  ammatory 
chemokine RANTES (Regulated upon activation, normal T-cell expressed, and secreted), which is known to enhance infl  ammatory processes such 
as arthritis and nephritis [49]. (C) Up-regulation of miR-21, miR-148, and miR-126 can either directly or indirectly inhibit DNA methyltransferase 1 
(DNMT1) levels. This inhibition in turn reduces the CpG methylation level and causes over-expression of autoimmune-associated genes in SLE, such 
as those encoding CD70, LFA-1 (CD11a) and EGFL7 (epidermal growth factor-like domain 7) [50,51]. An, poly-A tail; CH3, methyl groups; RASGRP1, 
RAS guanyl-releasing protein 1.
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expression of two matrix metalloproteinases (MMP-3 
and MMP-1) in RASFs, Stanczyk and colleagues [56] 
hypothesize that miR-155 may be involved in the 
modulation of joint destructive properties of RASFs, and 
in the control of the excessive tissue destruction due to 
inﬂ  ammation.  Th  e same group has recently identiﬁ  ed 
another miRNA, miR-203, highly expressed in RASFs 
and they demonstrated methylation-dependent regula-
tion of miR-203 expression. Moreover, high expression of 
miR-203 led to increased secretion of MMP-1 and IL-6 
via the NF-kB pathway, contributing to the activated 
phenotype of synovial ﬁ  broblasts in RA [58].
Two other miRNAs have been detected at high levels in 
RA. In particular, miR-223 is up-regulated in CD4+ naïve 
T lymphocytes of RA patients, and a possible role of this 
miRNA in the pathogenesis of the disease has been 
hypothesized [59]. Alsaleh and colleagues [60] studied 
the overexpression of miR-346 in RA ﬁ  broblast-like 
synoviocytes, showing that miR-346 indirectly regulates 
the release of the pro-inﬂ  ammatory cytokine IL-18.
Nakasa and colleagues [54] have studied the expression 
pattern of miR-146a in synovial tissue from patients with 
RA. Th  ey reported increased expression of mature 
miR-146a and primary miR-146a/b in RA synovial tissue, 
which also expressed TNF-α [54]. Cells positive for 
miR-146a are primarily CD68+ macrophages, but also 
some CD3+ T cell subsets and CD79a+ B cells [54]. Th  e 
expression of miR-146a/b is markedly up-regulated in 
RASFs after stimulation with TNF-α and IL-1β [54] 
(Figure 2a). Our group has implemented a diﬀ  erent 
approach to examine miRNA expression in RA patients 
compared to healthy controls [55]. Pauley and colleagues 
[55] have shown increased expression of miR-146a, 
miR-155, miR-132 and miR-16 in RA PBMCs. In 
addition, two targets of miR-146a, TRAF6 and IRAK1, 
are similarly expressed between RA patients and control 
individuals, despite increased expression of miR-146a in 
patients with RA. Repression of TRAF6 and/or IRAK1 in 
THP-1 cells resulted in up to an 86% reduction in TNF-α 
production, implying that normal miR-146a function is 
critical for the regulation of TNF-α production. Our data 
thus demonstrate that miRNA expression in RA PBMCs 
mimics that of synovial tissue/ﬁ   broblasts, and our 
hypothesis is that miR-146a is upregulated but unable to 
properly regulate TRAF6/IRAK1, leading to prolonged 
TNF-α production in RA patients [55]. More recently, 
Nimoto and colleagues [61] conﬁ  rmed the upregu  lation 
of miR-146 a/b in PBMCs of RA patients, which seems to 
be involved in the overexpression of the pro-inﬂ  am-
matory cytokine IL-17. Other groups have also demon-
strated the overexpression of miR-146a in CD4+ T cells 
from RA patients, which is closely related to TNF-α 
expression and to regulation of T-cell apoptosis, thus 
maintaining the pro-inﬂ  ammatory milieu typical of RA 
patients [62]. A recent report by Nakamachi and 
colleagues [63] has shown another miRNA, miR-124a, is 
involved in RA. Th   ey have found that miR-124a levels are 
signiﬁ  cantly decreased in RA synoviocytes compared to 
osteoarthritis synoviocytes. Transfection of precursor 
miR-124a into RA synoviocytes led to the signiﬁ  cant 
suppression of cell proliferation and arrest of the cell 
cycle at the G1 phase. Th  ey identiﬁ  ed a putative con-
sensus site for miR-124a binding in the 3’ UTR of cyclin-
dependent kinase 2 (CDK2) and monocyte chemo-
attractant protein 1 (MCP-1) mRNA. In fact, induction 
of miR-124a in RA synoviocytes signiﬁ  cantly suppressed 
the production of the CDK2 and MCP-1 proteins [63]. 
Th   us, these investigators show that miR-124a is also a key 
miRNA in the post-transcriptional regulatory mechanism 
of RA synoviocytes (Figure 2b).
Other autoimmune diseases
Sjögren’s syndrome
SS is an autoimmune inﬂ  ammatory exocrinopathy aﬀ  ect-
ing the lacrimal and salivary glands, leading to dry eyes 
and mouth [64]. It is often associated with positive anti-
SSA/Ro and anti-SSB/La antibodies and with other 
systemic symptoms, such as arthritis, lymphadenopathy, 
interstitial pneumonia, and renal disease [64]. Th   e role of 
miRNAs in SS has not been widely explored yet (Table 1). 
Alevizos and colleagues [65] identiﬁ  ed miRNA signatures 
from the minor salivary glands of patients with SS and 
normal controls. Th  is analysis allowed them to distin-
guish between these two populations, as well as between 
subsets of SS patients with low-grade or high-grade 
inﬂ  ammation [65]. Michael and colleagues [66] explored 
the presence of miRNAs in saliva exosomes isolated from 
parotid and submandibular glands of patients with SS. 
Th   ey have shown that miRNAs can be identiﬁ  ed in saliva, 
which suggests it may be possible to obtain information 
from these target organs without the need for invasive 
methods, such as biopsies. Th   e same group also identiﬁ  ed 
the miR-17-92 cluster as responsible for the accumulation 
of pro-B cells and the marked reduction of pre-B and 
more mature B cells in patients aﬀ   ected by SS [67] 
(Table 1). Alevizos and colleagues [68] also reported the 
impor  tance of miRNAs as biomarkers in SS, as they 
identiﬁ   ed a speciﬁ   c pattern of miRNA expression in 
inﬂ  amed salivary glands from SS patients with diﬀ  erent 
degrees of inﬂ  ammation. Th   is opens the possibility to use 
predicted target pathways of diﬀ  erentially  expressed 
miRNAs to identify either inﬂ   ammation or exocrine 
gland dysfunction. Recently, Pauley and colleagues [69] 
reported the altered expression of miR-146a in PBMCs of 
SS patients and an established mouse model of SS. In this 
report, miR-146a was signiﬁ  cantly overexpressed in SS 
patients compared with healthy controls, and functional 
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inﬂ  uence of miR-146a on increased phagocytic activity 
and suppressed inﬂ  ammation cytokine production. Th  is 
is another example of how altered miRNAs can inﬂ  uence 
pathogenetic mechanisms in autoimmune diseases such 
as SS.
Scleroderma
Another autoimmune disease in which miRNAs have not 
been widely studied is SSc, a multisystemic ﬁ  brotic dis-
order with high morbidity and mortality rates [70]. Th  e 
progressive replacement of normal tissue by collagen-
rich extracellular matrix leads to impairment and, ulti-
mately, to functional failure of aﬀ  ected organs. Fibro-
blasts are activated by proﬁ  brotic cytokines and growth 
factors, such as IL-4, transforming growth factor (TGF)-
β, and platelet-derived growth factor (PDGF)-B [71]. 
Maurer and colleagues [71] identiﬁ  ed miR-29 as one key 
regulator of collagen expression in SSc (Table 1). Th  is 
miRNA is strongly downregulated in SSc ﬁ  broblasts and 
skin sections, and transfection experiments showed a 
possible direct regulation of collagen by miR-29a. 
Moreover, TGF-β, PDGF-B, and IL-4 reduce the levels of 
miR-29a in normal ﬁ  broblasts to those seen in SSc ﬁ  bro-
blasts, while inhibition of PDGF-B and TGF-β pathways 
by treatment with imatinib restored the levels of miR-29a 
in vitro [71].
Polymyositis/dermatomyositis
PM/DM is a T-cell mediated inﬂ  ammatory myopathy in 
which the cellular immune response is a key feature in 
promoting muscle damage [72-74]. As in other systemic 
autoimmune diseases, a strong association of autoanti-
bodies with distinct clinical phenotypes is found in 
patients with PM/DM [75]. Th   e study of miRNAs in this 
disease is mainly limited to work by Eisenberg and 
colleagues [73] showing the possible inﬂ  uence of miR-
146b, miR-221, miR-155, miR-214, and miR-222 on the 
NF-kB pathway leading to muscle inﬂ  ammation 
(Table 1).
Figure 2. Aberrant expression of miRNAs in rheumatoid arthritis synoviocytes. (A) Contrary to peripheral blood mononuclear cells (PBMCs) 
from systemic lupus erythematosus patients, miR-146a is up-regulated in rheumatoid arthritis (RA) synoviocytes and PBMCs. miR-146a is a known 
regulator of IRAK1 (IL-1 receptor-associated kinase 1) and TRAF6 (TNF receptor-associated factor 6) mRNA and this may be responsible for the 
altered regulation of IRAK1 and TRAF6, both of which act through the NF-kB pathway to prolong the production of proinfl  ammatory cytokines 
and chemokines, including TNF-α and IL-1β [3,55]. (B) miR-124a is down-regulated in synoviocytes from RA patients. Its target proteins, CDK2 
(cyclin-dependent kinase 2) and MCP-1 (monocyte chemoattractant protein 1), are up-regulated and this leads to increased synovial proliferation, 
angiogenesis and chemotaxis [63].
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miRNAs play important roles in fundamental cellular 
processes, and their dysregulated expression is observed 
in diﬀ  erent pathological conditions, including rheumatic 
diseases, inﬂ  ammation, and tumorigenesis [31]. Th  e  use 
of miRNAs or miRNA-mimic oligonucleotides has been 
tested in diﬀ  erent cancer cell lines, in mice, and in non-
human primates [31]. Th   ese previous investigations have 
shown that miRNA-based gene therapies targeting 
dysregulated miRNAs have the potential to become 
therapeutic tools. It will be interesting if these miRNA-
based gene therapies will be developed to treat patients 
with rheumatic diseases, such as RA and SLE, in the 
future. However, further studies in multiple populations 
and conducted by independent investigators are needed 
to validate and elucidate these mechanisms and whether 
or not miRNAs could serve as useful disease markers or 
therapeutic targets.
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